UnknownPhase 1

AMT-151 in Patients With Selected Advanced Solid Tumours

Australia30 participantsStarted 2023-01-25

Plain-language summary

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel antibody-drug conjugate against folate receptor alpha, in patients with selected advanced solid tumors.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Serous, endometrioid, clear-cell, or mucinous epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
✓. Serous, endometrioid, or clear-cell endometrial cancer.
✓. Adenocarcinoma of the lung.
✓. Triple-negative breast cancer.
✓. Pancreatic ductal adenocarcinoma.
✓. Malignant pleural mesothelioma.

What they're measuring

Recommended Phase 2 Dose (RP2D)

Timeframe: Up to 24 months

Maximum Tolerated Dose (MTD)

Timeframe: Up to 24 months

Incidence of Adverse Events

Timeframe: Up to 24 months

Trial details

NCT IDNCT05498597

SponsorMultitude Therapeutics Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-01-01

Contact for this trial

Jane Zhu

13917933915 juanjuan.zhu@multitudetherapeutics.com

View on ClinicalTrials.gov More Advanced Solid Tumor trials